Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BTF3, initially discovered as a factor required for transcription inititation of RNA polymerase II, is expressed in two isoforms, termed a and b.
BTF3b
, the transcriptionally inactive isoform, was identified as an interaction partner of protein kinase CK2 subunit beta employing the interaction trap system for screening ofa HeLa cDNA fusion library. We report here on the interaction between the other isoform,
BTF3a
, and protein kinase CK2. The complete cDNA of
BTF3a
was cloned by RT-PCR and used for analysis in the two-hybrid system with a three-reporter yeast strain. Interaction of
BTF3a
with CK2 subunits alpha, alpha' or beta was detectable by one of three reporters, whereas the CK2beta -
BTF3a
interaction was activating two reporters. It was also shown that
BTF3a
is phosphorylated in vitro by the alpha2beta2 holoenzyme, but not by alpha or alpha' alone, indicating the requirement of beta for substrate recognition. Immunoprecipitations of
GST
-fused
BTF3a
carried out in vitro resulted in co-precipitation of beta. Similarly,
GST
-
BTF3a
, but not
GST
alone isolated with glutathione agarose beads from buffer containing recombinant CK2 subunits was found complexed with alpha and beta, likely representing alpha2beta2 holoenzyme. The data show a weak, nevertheless specific interaction of protein kinase CK2 via subunit beta with the putative transcription factor
BTF3a
in vitro and in vivo, and a role of
BTF3a
as a potential new substrate for CK2.
...
PMID:BTF3 is a potential new substrate of protein kinase CK2. 1009